<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>According to a recently reported study, <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy appears to be ineffective in thrombotic cerebrovascular disease when viewed from the standpoint of mortality, although it does control <z:mp ids='MP_0005048'>thrombosis</z:mp> in animals, recurrent ischemic attacks and progression of infarction in patients with <z:e sem="disease" ids="C0038131,C0038506" disease_type="Disease or Syndrome;Sign or Symptom" abbrv="">stuttering</z:e> <z:hpo ids='HP_0001297'>strokes</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The efficacy of <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy in preventing a catastrophic <z:hpo ids='HP_0001297'>stroke</z:hpo> is analyzed in the present report </plain></SENT>
<SENT sid="2" pm="."><plain>Of 92 untreated patients followed up for an average period of 36 months, 28 suffered a recurrent <z:hpo ids='HP_0001297'>stroke</z:hpo>, only two of these being trivial </plain></SENT>
<SENT sid="3" pm="."><plain>One trivial and 12 catastrophic <z:hpo ids='HP_0001297'>strokes</z:hpo> occurred in the first 16 months </plain></SENT>
<SENT sid="4" pm="."><plain>Of 103 patients treated with <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> for an average period of 16 months, seven had recurrent <z:hpo ids='HP_0001297'>strokes</z:hpo>, but five of these were trivial </plain></SENT>
<SENT sid="5" pm="."><plain>In the first 16 months one catastrophic and four trivial <z:hpo ids='HP_0001297'>strokes</z:hpo> occurred </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="3" ids="50249">Anticoagulant</z:chebi> therapy appears to be useful in preventing catastrophic <z:hpo ids='HP_0001297'>strokes</z:hpo> in selected patients in whom the risk of recurrent <z:hpo ids='HP_0001297'>strokes</z:hpo> justifies the risks involved in this treatment </plain></SENT>
</text></document>